A molecular classification for malignant mammary tumors has been described according to the immunohistochemical co-expression of ERα, epidermal growth factor receptor 2 (EGFR-2/HER-2), and baseline biomarkers such as CK14 and p63. Here, ESR1 is linked to cancer.